Month: September 2026

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants.

Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW Nasdaq listing.

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully exercised at the $6.43 strike price.

Key dates and terms:

• Expiration date: September 30, 2026 5PM ET
• Strike price: $6.43 per warrant
• Warrants outstanding: 910,904
• No extension. No repricing.

Shareholders and warrant holders are advised to act before the deadline if they intend to exercise. Nutriband will continue to provide updates on Company developments in the coming weeks.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

Novacium was selected based on the performance of its very high-capacity GEN 3 and GEN 4 cylindrical cells, designed for high-capacity battery applications. The contract was awarded at the end of June 2026

MONTREAL and SOLAIZE, France, Sept. 22, 2026 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08) is pleased to inform its shareholders that its strategic partner, NOVACIUM SAS, a French deep-tech company specializing in green engineering of materials for energy applications, has announced that the French Army Technical Section (“STAT”) awarded it a contract ^[1] at the end of June 2026 for the development and supply of high-capacity prototype batteries to be evaluated in tactical radios. For procedural reasons, the award could not be announced prior to today.

From Initial Evaluation to Contract Award: More Than Eighteen Months of Technical Collaboration

In August 2024, STAT, the French Army organization responsible for evaluating and qualifying equipment for land forces, contacted Novacium after reviewing published results from cells developed using its silicon-based anode material. The organization sought to evaluate the possibility of integrating Novacium’s cells into the batteries used in its tactical radios.

Following six months of internal development, Novacium’s teams developed two battery prototypes, which were provided to STAT in April 2025. The initial results were conclusive: with comparable form factors and interfaces, energy capacity increased by 23% compared with the reference battery.

Image 1) Photos illustrating the use of Novacium’s high-capacity batteries

Building on these results, in September 2025 Novacium met with France’s Directorate General of Armaments (DGA), Defence Innovation Agency (AID), and STAT to propose a work program to develop very high-capacity prototype batteries.

Several months of discussions followed to refine the program around an ambitious objective: significantly increasing, or potentially doubling, the energy capacity of tactical radio batteries without modifying existing connectors, chargers, or interfaces. This work resulted in a contract award to Novacium at the end of June 2026.

Selection Based on the Performance of Novacium’s High-Capacity Cells

Novacium was selected based on the performance of its very high-capacity GEN 3 and GEN 4 cylindrical cells, designed for high-capacity battery applications. This distinctive energy density made it possible to propose a solution capable of meeting STAT’s objective: significantly increasing the operating time of tactical radios without disrupting existing charging infrastructure, procedures or the logistics chain.

The contract provides for delivery in successive batches, structured around operational field feedback (RETEX). The first batch of prototypes will undergo an evaluation campaign under operational conditions, after which STAT and Novacium will jointly prepare a detailed RETEX. Lessons learned from this evaluation will guide design adjustments before production of a second batch that will better reflect a series-production configuration.

Image 2) Novacium battery for tactical radios and GEN 4 21700 cells

“The award of this contract by STAT represents an important recognition of Novacium’s expertise in designing high-performance cells and batteries for demanding environments. We were selected because our GEN 3 and GEN 4 cells offer a distinctive energy density capable of meeting particularly demanding specifications. This program illustrates our strategy: applying our materials and battery expertise to critical defence and security applications,” said Dr. Jed Kraiem, Ph.D., Chief Operating Officer of Novacium.

Potential Applications with Other Allied Forces

The expertise deployed under this program (high-capacity cell integration, battery management system adaptation and enclosure design) could be applied to other battery formats for tactical radios used by the armed forces of NATO member countries. A successful evaluation by STAT could serve as a technical reference to support this approach. However, each adaptation would remain subject to the relevant platform’s specific requirements, qualification testing, and separate procurement decisions.

“Novacium’s selection by the French Army’s technical organization responsible for equipment evaluation and qualification represents an important step in validating its expertise,” said Bernard Tourillon, President and CEO of HPQ Silicon Inc., which serves as President of Novacium. “If the evaluation phase confirms the expected performance, this program could become a relevant technical reference for presenting the solution to other allied forces with comparable requirements. For HPQ, every advance Novacium makes in the defence sector also strengthens the strategic value of our 36.8% interest in Novacium, as well as the potential to commercialize in North America the technologies covered by our licensing agreement.”

This contract is part of the continued development of Novacium’s activities in the defence and autonomous systems sectors. It follows the August 19, 2026, announcement of a first order for battery packs intended to power drones to be delivered to a French Army regiment through LN’INNOV.

Additional Information:

[1] A “marché,” in the context of French public procurement, refers to a paid contract entered between a public purchaser and an economic operator to meet a requirement for works, supplies or services in exchange for a price or equivalent consideration. In this case, the contract awarded to Novacium covers the development and supply, in successive batches, of prototype batteries intended for evaluation by STAT. The financial terms and quantities covered by the contract are subject to confidentiality obligations and are not disclosed.

About Novacium SAS

Novacium is a French deep-tech company based in Solaize, specializing in the development and production of silicon-based anode materials for lithium-ion batteries using a proprietary process. Novacium also designs custom battery cells and packs for demanding applications, particularly in the defence, aerospace and portable energy sectors.

About HPQ Silicon

HPQ Silicon Inc. is a Quebec-based industrial issuer listed on the TSX Venture Exchange (TSX-V: HPQ), focused on innovation in advanced materials and the development of critical processes.

HPQ holds a strategic 36.8% interest in Novacium, its research, development and commercialization partner. Together, HPQ and Novacium are developing next-generation silicon-based anode materials (Gen3 and Gen4) for batteries, pursuing the commercialization of ENDURA+ lithium-ion cells, and developing innovative technologies for clean hydrogen production and the energy recovery of waste materials. HPQ holds the exclusive rights to commercialize these technologies in North America.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements based on certain assumptions regarding technological performance, market demand, permitting, financing, supply chains and economic conditions. These statements involve significant risks, including delays, regulatory issues, competition, availability of financing and macroeconomic uncertainties. Actual results could differ materially from those anticipated. Detailed risk factors are presented in HPQ’s Annual Information Form available on SEDAR+. Forward-looking statements are provided solely to outline management’s future expectations and objectives. A more detailed cautionary note regarding forward-looking information related to the HPQ Endura+ batteries project is available for download [here]. Additional information regarding the Company is available on SEDAR+ (www.sedarplus.ca) and on the Company’s website at www.hpqsilicon.com/.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact Information

NOVACIUM SAS
Dr. Jed Kraiem, Ph.D., Chief Operating Officer
info@novacium.com

HPQ Silicon Inc.
Bernard J. Tourillon, BAA, MBA, President and CEO
info@hpqsilicon.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a8db8169-0afd-4ee5-945b-d6606238f077
https://www.globenewswire.com/NewsRoom/AttachmentNg/a4942b78-d043-4fe3-9c99-91b31b691b30 

AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, will host a live webcast and product demo for financial analysts and investors on Wednesday, October 14, 2026, at 12:00 p.m. Eastern Time.

The webcast will provide a comprehensive recap of the strategic product introductions and platform capabilities unveiled at Navigate, SailPoint’s premier annual identity security conference.

The webcast will be available on SailPoint’s website at investor.sailpoint.com.  A replay of the webcast will be available on the investor relations website for one year.

Additionally, keynotes and mainstage sessions live from Navigate in Austin (October 5–8) will be streamed in real-time, learn more at sailpoint.com/navigate/austin.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Investor Relations Contact
Scott Schmitz, SVP IR
ir@sailpoint.com

Media Relations Contact
Shannon Paulk, Sr. Manager, Corporate Communications
shannon.paulk@sailpoint.com

• Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027
• Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigators
• Ongoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution

AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s investigational new drug (IND) application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027.

“With the clinical hold lifted, we can now execute our development plan for simufilam in TSC-related epilepsy,” said Rick Barry, President and Chief Executive Officer of Filana. “While on hold, we completed key trial-readiness activities, including engaging a leading clinical research organization, identifying clinical trial sites, and recruiting potential investigators. With investigational drug supply in place, implementation of our Phase 2a study of simufilam is now able to progress expeditiously toward site initiation and patient enrollment.”

“Drug-resistant epilepsy remains a challenge for a majority of individuals affected by TSC,” said Kari Luther Rosbeck, President and Chief Executive Officer of the TSC Alliance. “Research investigating different molecular pathways involved in TSC offers hope for potential new options for those living with the disease. The TSC Alliance applauds Filana for their innovative work in exploring a new target mechanism and their plans to launch a clinical trial to test the effectiveness of that potential new treatment to help address a major unmet need for the TSC community.”

Planned Phase 2a Trial Design

Filana’s Phase 2a study is a 16-week multicenter, randomized, double-blind clinical trial to evaluate two doses of simufilam in patients with refractory TSC-related seizures. The study is planned to be conducted at 13 sites in the U.S. with a target enrollment of 40 subjects aged 12 to 55. All subjects who complete the double-blind treatment phase are eligible to participate in a 48-week extension study.

The study is designed to assess safety, tolerability, pharmacokinetics, and seizure-related measures, including seizure frequency, seizure intensity and duration, nighttime seizures, and sleep-related outcomes. Data from the study are expected to help inform the development path for simufilam in TSC-related epilepsy, including the design of future studies in younger patient populations.

Scientific Rationale

Simufilam is an oral small molecule intended to modulate the filamin A protein. The clinical evaluation of simufilam in TSC-related epilepsy is supported by findings from two preclinical mouse models. Initial studies were conducted in the laboratory of Angélique Bordey, PhD, Rothberg Professor of Neurosurgery at Yale School of Medicine and Senior Vice President, Neuroscience at Filana. Those studies showed that simufilam reduced seizure frequency in a mouse model of focal onset seizures involving TSC-related pathology¹. In a separate study conducted with the TSC Alliance Preclinical Consortium using a well-accepted TSC-knockout mouse model, simufilam attenuated the progression of seizure activity in a dose-dependent manner².

Filana holds an exclusive worldwide license from Yale University to intellectual property supporting the use of simufilam in TSC-related epilepsy.

About TSC and TSC-Related Epilepsy

TSC is a rare genetic disorder resulting from a mutation in the TSC1 or TSC2 gene. These mutations affect the mechanistic target of rapamycin (mTOR) pathway and can cause tumors to grow in multiple organs^3,4. Epilepsy is the most common health issue affecting the TSC community, with 80% to 90% of TSC patients experiencing seizures⁵. TSC-related epilepsy affects approximately 45,000 people in the U.S.^1,3. Most patients start having seizures within their first year of life¹. Even with multiple approved treatments, more than 60% of TSC patients remain refractory to antiepileptic therapy⁶.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. (NASDAQ: FLNA), is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.

For more information, please visit: https://www.FilanaTx.com

References:

1. Zhang L, Huang T, Teaw S, Nguyen LH, Hsieh LS, Wong X, Burns LH, Bordey A. Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations. Science Translational Medicine. 2020;12(531):eaay0289. DOI: 10.1126/scitranslmed.aay0289
2. Stansley B, Islam MM, Aguiar DJ, Fuchs Z, Catron M, Morairty S, et al. The small molecule simufilam dose-dependently attenuates the worsening of seizures in a mouse model of tuberous sclerosis complex. Epilepsia. 2026;00:1–13. DOI: 10.1002/epi.70227
3. https://www.tscalliance.org/understanding-tsc/what-is-tsc/
4. https://www.tscalliance.org/understanding-tsc/genetics/
5. Crino P, Nathanson K, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-1356. DOI: 10.1056/NEJMra055323
6. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236–1241. DOI: 10.1111/j.1528-1167.2009.02474.x

For More Information Contact:
Investors
Mike Moyer
mmoyer@lifesciadvisors.com

Filana Therapeutics
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@FilanaTx.com
IR@FilanaTx.com

Cautionary Note Regarding Forward-Looking Statements:

This news release contains forward-looking statements that may include but are not limited to statements regarding: the timing and plans to initiate and conduct clinical studies with simufilam in TSC-related epilepsy; the design, structure, duration, objectives, endpoints, patient population, conduct, enrollment, completion, and potential results of our planned Phase 2a clinical trial; our ability to work with clinical research organizations, clinical sites, patient advocacy organizations, and the TSC community to advance the trial efficiently; the potential for simufilam as a treatment for TSC-related epilepsy and other potential indications; and the timing of anticipated milestones, including announcing study sites and screening patients. These statements may be identified by words such as “anticipate”, “before”, “believe”, “could”, “expect”, “forecast”, “intend”, “may”, “pending”, “plan”, “possible”, “potential”, “prepares for”, “will”, and other words and terms of similar meaning.

Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to our ability to initiate, enroll, conduct, and complete the planned Phase 2a study of simufilam in TSC-related epilepsy; our ability to engage clinical trial sites and participants; our ability to work effectively with clinical research organizations, vendors, investigators, patient advocacy organizations, and the TSC community; potential changes to the clinical trial protocol, trial design, endpoints, timing, patient population, or development plans; our ability to generate clinical data that support further development of simufilam; risks inherent in drug discovery and development; and other risks specific to Filana Therapeutics, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at www.sec.gov.

All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.

Our clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.

We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.

Site II would add approximately $391 million in base-term contracted revenue to previously announced base-term contracted revenue of $1.25 billion for Site I. 

NEW YORK, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) — Host Digital Inc. (NYSE American: HOST) (“Host Digital” or the “Company”), a vertically integrated digital infrastructure company that develops, acquires, owns, and operates institutional-quality, RightScaled data centers for artificial intelligence (“AI”) and high-performance computing (“HPC”), began trading on Friday, September 18 on the NYSE American under the ticker symbol “HOST.”

Host Digital also announced that it has signed a Preferential Rights Agreement with its Sponsor, which provides Host Digital with a right of first offer and a right of first refusal on qualifying data center projects held by its Sponsor. Host Digital expects to acquire from the Sponsor a second data center facility, also located in northeast Oklahoma (“Site II”). The Sponsor has signed a 12-year take-or-pay lease for Site II, with a publicly traded AI cloud provider, for approximately 20 MW of gross / 16 MW of critical IT load, representing approximately $391 million in base-term rent, or approximately $819 million over a total 22-year term assuming all renewal options are exercised, which is expected to be supported by a lease backstop from an investment-grade publicly listed U.S.-based global technology company.

Any contribution of Site II remains subject to negotiation and the execution of definitive agreements, and no assurance can be given that it will occur.

TRANSACTION AND LEASE HIGHLIGHTS

• Merger completed: Host Digital completed its merger with Host Digital Infrastructure LLC on September 17, 2026. Following the Closing of the priced offering, HOST’s outstanding share count is 48,088,414, which implies a market capitalization of $384,947,754.07 as of market close on September 21, 2026.
• Trading as HOST: Shares began trading on the NYSE American under the ticker symbol “HOST” on Friday, September 18, 2026.
• Site I: With the closing of the merger, Site I is now owned by Host Digital. The fully executed 15-year, take-or-pay lease is for 55 MW gross / 43 MW of critical IT load, representing approximately $1.25 billion in base-term contracted revenue, or approximately $3.2 billion over a 30-year total term if all renewal options are exercised, and a Year 1 contracted revenue of $67 million, with delivery expected in the first quarter of 2027. The terms also include a 3.0% annual rent escalator with the tenant bearing operating expenses. The lease is expected to be supported by a lease backstop from an investment-grade publicly listed U.S.-based global technology company.
• Site II: Host Digital expects to acquire from the Sponsor a second data center facility, also located in northeast Oklahoma (“Site II”), pursuant to its rights under the Preferential Rights Agreement. The Sponsor has signed a 12-year take-or-pay lease with a publicly traded AI cloud provider for approximately 20 MW gross / 16 MW of critical IT load, representing approximately $391 million in base-term rent, or approximately $819 million over a total 22-year term assuming all renewal options are exercised, and Year 1 contracted revenue of $28.3 million. The terms also include a 2.5% annual rent escalator with the tenant bearing operating expenses. The lease is expected to be supported by a lease backstop from a different investment-grade publicly listed U.S.-based global technology company. The contribution of Site II remains subject to negotiation and the execution of definitive agreements.[1]
• Sponsor relationship: Under the Preferential Rights Agreement, Sponsor provided the Company with a 24-month exclusive right of first offer and right of first refusal on qualifying data center assets from the Sponsor’s pipeline, which includes an additional 450 MW of RightScaled data center assets with the potential ability to be delivered to tenants in 2027, as well as longer-term, “land and expand” growth from both grid and behind-the-meter expansions at existing sites, followed by the potential development of larger scale projects which may potentially be delivered to tenants in 2028 and beyond.
• Differentiated approach: Host Digital expects to target a combination of RightScaled, 20-100 MW grid-powered assets with existing or near-term electricity in place, which it expects to be able to deliver to tenants in 2026, 2027 and 2028, and which can potentially be expanded with additional utility capacity and behind-the-meter private grid generation, along with larger scale opportunities which may potentially be delivered in 2028 and beyond. This “barbell” approach aims to accelerate revenue by emphasizing speed to power, while maximizing opportunities for scale over time. The Company focuses on rapidly delivering “turnkey” facilities, which go beyond a typical powered shell to meet tenants, chipmakers and end users where they are, in what the Company considers a “sweet spot” of development cost and lease rates.

“Host Digital is entering the public markets with the three things that matter most in AI infrastructure today: access to power, contracted demand, and a model we can repeat,” said Shawn Matthews, Chairman of Host Digital. “At our initial site, we have 43 MW of critical IT load committed under a long-term lease. We now have started negotiations to acquire a second energized and leased facility. If we complete that acquisition, Host Digital expects to have approximately 59.3 MW of total contracted critical IT load and an aggregate of $1.64 billion in base-term contracted revenue across the two sites. Our listing on the New York Stock Exchange American gives us a public-markets platform to continue building that portfolio with discipline.”

“Infrastructure is ultimately constrained by how quickly operators can secure power and bring capacity online,” said Harmol Samra, Chief Executive Officer of Host Digital. “The Host Digital platform’s strategy addresses this constraint. We target acquiring sites where power is already flowing or available in the near term, then develop against long-term contracted demand, rather than building speculative capacity and hoping tenants follow. Site II is exactly the type of asset our RightScaled strategy was designed to capture: energized infrastructure, a modular design, contracted demand, and a defined path to tenant delivery.”

Host Digital’s development model centers on RightScaled sites of approximately 20 MW to 100 MW with grid power available today or in the near term, supplemented by behind-the-meter generation where appropriate, and developed against long-term contracted demand from strong or credit-enhanced counterparties. The strategy is designed to bring new capacity to market in months rather than years while avoiding many of the interconnection, permitting, and infrastructure constraints facing larger greenfield developments.

Host Digital expects to own and control the core physical infrastructure at each facility, including the real estate, power and interconnection rights, utility agreements, electrical systems, and cooling infrastructure. Tenants are expected to control their own compute infrastructure and model layers, allowing Host Digital to operate as the underlying digital infrastructure and real estate platform rather than taking technology or compute risk.

PREFERENTIAL RIGHTS AGREEMENT

In connection with the closing of the merger, Host Digital entered into a Preferential Rights Agreement with its Sponsor, an entity formed and controlled by the founders of Host Digital Infrastructure LLC. For 24 months, the agreement gives Host Digital exclusive rights of first offer and first refusal on data center assets the Sponsor acquires or develops and intends to place in a public company vehicle. The Sponsor’s potential pipeline includes four additional sites with more than 450 MW of gross power capacity targeted for delivery in 2026 and 2027, including more than 350 MW of grid power and more than 100 MW of behind-the-meter capacity.

Any contributions of additional sites remain subject to negotiation and the execution of definitive agreements, and no assurance can be given that they will occur.

EXPERIENCED LEADERSHIP

Shawn Matthews
Chairman of the Board of Directors

Shawn Matthews has over 30 years of management experience in public and private corporations, with diverse experience across energy and financial sectors. His leadership experience includes serving as CEO of Cantor Fitzgerald & Co. from 2009 to 2018; as founder and CEO of Hondius Energy; as CEO of Mercator Power; and as sponsor of Terrestrial Energy and a former member of its board of directors. Mr. Matthews has deep expertise and connectivity across the energy and real estate sectors, and capital markets more broadly, and brings strong governance leadership to HOST.

Harmol Samra
Chief Executive Officer

Harmol Samra has over a decade of experience in real estate private equity and digital infrastructure development, and previously served in roles at Starwood Capital and ICONIQ Capital in San Francisco and New York. At ICONIQ, Mr. Samra helped build and oversee IPI Partners, which grew to become one of the largest data center development platforms in the world. At the time of its sale to Blue Owl in 2024, IPI had a portfolio of 82 data centers comprising more than 2.2 gigawatts of leased capacity globally. Mr. Samra has significant expertise in developing real estate and digital infrastructure projects, and deep relationships across the AI/HPC and AI infrastructure universe. Mr. Samra previously held investment and investment banking roles, respectively, at PGIM, the global asset management business of Prudential Financial, Inc., with over $1.4 trillion in assets under management, and Morgan Stanley.

ABOUT HOST DIGITAL

Host Digital Inc. (NYSE American: HOST) develops, acquires, owns, and operates institutional-quality data centers in the United States that support AI and HPC workloads. The Company focuses on RightScaled sites of 20 MW to 100 MW with existing or near-term access to power, leased under long-term contracts to strong or credit-enhanced counterparties. Host Digital seeks to own and control the real estate, power, and data center infrastructure at each site, and provides turnkey facilities where tenants select and deploy their own compute infrastructure and model layers.

Through its wholly owned subsidiaries, the Company also operates a portfolio of 19 natural and organic grocery stores across six states under the Ada’s Natural Market, Paradise Health & Nutrition, Mother Earth’s Storehouse, Greens Natural Foods, Ellwood Thompson’s, and GreenAcres Market brands. Healthy Choice Wellness Corp.’s natural and organic grocery business continues to operate as a division of the Company following the merger.

For more information, visit www.hostdigital.ai.

Footnote

1. Any contribution of Site II remains subject to negotiation and the execution of definitive agreements, and no assurance can be given that it will occur.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed acquisition and development of one or more data center facilities, including the potential acquisition of Site II; the expected assets leases and other assets to be acquired from the Sponsor or any other third party; the timing of delivery of the Company’s data center facilities to tenants; anticipated contracted revenue, lease terms and renewal options; the Company’s development strategy and ability to execute and scale its business model; and the Sponsor’s potential pipeline and contribution of additional data center assets to the Company. Statements that are not historical facts are based on current estimates, assumptions and projections and are not guarantees of future performance. Words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “will,” “would,” “could” and similar expressions identify forward-looking statements, although not all forward-looking statements contain these words.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks relating to the completion of the offering on the anticipated terms or at all; the Company’s ability to satisfy the applicable listing requirements; the Company’s ability to successfully integrate the businesses and realize the anticipated benefits of the offering; the Company’s ability to obtain required financing, complete development and deliver capacity on schedule; and other factors described in the Company’s filings with the SEC, including under the header “Risk Factors” in Exhibit 99.2 to the Current Report on Form 8-K filed with the SEC on September 17, 2026. The Company undertakes no obligation to update these statements except as required by law.

MEDIA CONTACT
Jessica Starman
jessica@elev8newmedia.com
888-461-2233

INVESTOR CONTACT
Jason Assad
info@bridge-comms.com

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therapies.

Marker previously selected Cellipont Bioservices as its manufacturing partner for MT-601 (neldaleucel) to support the continued clinical development and prepare for potential pivotal-stage and commercial manufacturing requirements.

Kincellis was formed through the combination of Cellipont Bioservices and Kincell Bio, creating a U.S.-based contract development and manufacturing organization (CDMO) focused on cell therapies and other advanced modalities. Announced on September 17, 2026, the combination created a larger advanced-therapies CDMO with approximately 140,000 square feet of development and manufacturing infrastructure and 16 operational, qualified GMP manufacturing suites across three U.S. locations. The combined organization also brings together broader scientific and technical expertise, an expanded manufacturing network and additional financial resources to support programs from clinical development through commercial supply.

Marker believes these expanded capabilities further strengthen and de-risk the manufacturing foundation for MT-601 as the program advances toward later-stage clinical development.

“We congratulate the Cellipont and Kincell teams on the formation of Kincellis Advanced Therapies,” said Juan Vera, MD, President and Chief Executive Officer of Marker Therapeutics. “The combination creates a stronger manufacturing partner, and we look forward to continuing our work with the team as MT-601 advances into its next stage of clinical development.”

MT-601 (neldaleucel) is currently investigated in the Company’s Phase 1 APOLLO study (clinicaltrials.gov identifier: NCT05798897) in patients with lymphoma who have relapsed after anti-CD19 chimeric antigen receptor (CAR)-T cells or are not candidates for anti-CD19 CAR-T cell therapies. Marker previously reported a favorable safety profile and encouraging clinical activity from the dose-escalation portion of the study demonstrating a 66% objective response rate among 12 patients with Non-Hodgkin Lymphoma (NHL), with 50% achieving complete remission (Press Release, August 26, 2025).

“Establishing a robust and scalable manufacturing platform is an important component of advancing MT-601 through late-stage clinical development,” Dr. Vera continued. “Kincellis’ expanded U.S. footprint, advanced cell therapy expertise and capabilities spanning clinical development through potential commercial supply align well with our long-term strategy and the evolving manufacturing needs of the MT-601 program.”

“We are proud to continue supporting Marker and the advancement of MT-601,” said Darren Head, Chief Executive Officer of Kincellis Advanced Therapies. “Marker will continue to work with the team that understands its program, now supported by the broader expertise, resources and manufacturing network of Kincellis. This combination allows us to provide continuity today while preparing to support Marker’s evolving needs as the program advances.”

About Neldaleucel (MT-601)
The Company’s lead product, MT-601, is a multi-antigen recognizing (MAR) T cell product that utilizes a non-genetically modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4). Marker is currently investigating MT-601 in the Company-sponsored Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897) for the treatment of patients with lymphoma who have relapsed after or are not candidates for anti-CD19 CAR-T cell therapies.

About APOLLO
The APOLLO trial (clinicaltrials.gov Identifier: NCT05798897) is a Phase 1, multicenter, open-label study designed to evaluate the safety and efficacy of neldaleucel (MT-601) in participants with relapsed or refractory lymphoma. The primary objective of the exploratory Phase 1 clinical trial is to evaluate the optimum dose, safety, and preliminary efficacy of neldaleucel in participants with various lymphoma subtypes. The APOLLO study is supported by the National Cancer Institute of the National Institutes of Health (Award Number R44CA291521) and the U.S. Department of War (formerly U.S. Department of Defense).

About MAR-T cells
The multi-antigen recognizing (MAR) T cell platform (formerly multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research, including the National Cancer Institute of National Institutes of Health, U.S. Department of War, the FDA Orphan Drug program and the Cancer Prevention Research Institute of Texas (CPRIT).

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

About Kincellis Advanced Therapies
Kincellis Advanced Therapies is a U.S.-based contract development and manufacturing organization supporting advanced-therapy developers from early-stage CMC, process and analytical development through clinical supply, pivotal-stage programs and commercial supply. With facilities in Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas, Kincellis combines broad technical expertise with flexible, scalable GMP infrastructure across autologous and allogeneic therapies, including but not limited to CAR-T, Tregs, CAR-NK, MSCs, dendritic cell vaccines, exosomes, iPSCs & synthetic mRNA.

Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including neldaleucel (MT-601) for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

Media and Investor Contact
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com

Approval of BRAVNETSA expands radioligand treatment options for adult patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to LUTATHERA^® (lutetium Lu 177 dotatate). BRAVNETSA is indicated for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

“As the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA approved in the United States, BRAVNETSA’s approval marks an important milestone for Lantheus as we continue to expand our radiopharmaceutical portfolio, bringing additional treatment options to people living with GEP-NETs,” said Mary Anne Heino, Executive Chairperson and CEO, Lantheus. “We are focused on a thoughtful launch and ensuring the right commercial and operational capabilities are in place to support reliable supply and broad patient access.”

BRAVNETSA was approved through the FDA’s Abbreviated New Drug Application (ANDA) pathway. As part of this review, BRAVNETSA is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, LUTATHERA.

“For more than 70 years, Lantheus has helped define what’s possible in radiopharmaceuticals. As the first radioligand therapy approved through the ANDA pathway, BRAVNETSA represents a breakthrough for our industry and opens a new regulatory pathway for innovation,” said Ludger Dinkelborg, PhD, Head of Research and Development, Lantheus. “Innovation comes in many forms, and this approval reflects Lantheus’ ability to apply our deep radiopharmaceutical expertise in navigating the ANDA process and gives clinicians another FDA-approved option to support treatment decisions based on each patient’s needs.”

Visit www.BRAVNETSAhcp.com for more information on when the product will be available.

About GEP-NETs

Neuroendocrine tumors (NETs) are rare, often slow-growing cancers that can develop throughout the body. A subset known as gastroenteropancreatic NETs (GEP-NETs) affects the digestive system and pancreas and may be functional or non-functional depending on hormone activity.¹ Over the last few decades, the incidence of GEP-NETs has increased significantly, with the prevalence in the U.S. estimated to be approximately 200,000 patients.² Because GEP-NETs often grow slowly and cause non-specific symptoms, up to 50% are initially misdiagnosed, with patients waiting an average of 4.3 years from symptom onset to diagnosis.^3,4  

About BRAVNETSA

BRAVNETSA (lutetium Lu 177 dotatate), previously referred to as PNT2003, is bioequivalent and therapeutically equivalent to LUTATHERA.

INDICATION

BRAVNETSA is indicated for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

Pediatric use information is approved for Advanced Accelerator Applications USA INC’s LUTATHERA (lutetium Lu 177 dotatate) injection for intravenous use. However, due to Advanced Accelerator Applications USA Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

IMPORTANT SAFETY INFORMATION IN ADULTS

WARNINGS AND PRECAUTIONS

Risk From Radiation Exposure

BRAVNETSA contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer.

Radioactivity may be detected in the urine for up to 30 days following BRAVNETSA administration. Minimize radiation exposure in patients, medical personnel, and household contacts during and after treatment with BRAVNETSA consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient release guidance, and provide instructions to the patient for follow-up radiation protection at home.

Myelosuppression        

In NETTER-1, myelosuppression occurred more frequently in patients receiving lutetium Lu 177 dotatate injection with long-acting octreotide compared with patients receiving high-dose, long-acting octreotide (all Grades/Grade 3 or 4): anemia (81%/0% vs 54%/1%), thrombocytopenia (53%/1% vs17%/0%), and neutropenia (26%/3% vs11%/0%). In NETTER-1, platelet nadir occurred at a median of 5.1 months following the first dose. Of the 59 patients who developed thrombocytopenia, 68% had platelet recovery to baseline or normal levels. The median time to platelet recovery was 2 months. Fifteen of the 19 patients in whom platelet recovery was not documented had post-nadir platelet counts. Among these 15 patients, 5 improved to Grade 1, 9 to Grade 2, and 1 to Grade 3. Monitor blood cell counts. Withhold dose, reduce dose, or permanently discontinue BRAVNETSA based on the severity of myelosuppression.

Secondary Myelodysplastic Syndrome and Leukemia

In NETTER-1, with a median follow-up time of 76 months in the main study, myelodysplastic syndrome (sMDS) was reported in 2.3% of patients receiving lutetium Lu 177 dotatate injection with long-acting octreotide compared with no patients receiving high-dose, long-acting octreotide. In ERASMUS, 16 patients (2%) developed sMDS and 4 (0.5%) developed acute leukemia. The median time to onset was 29 months (9 to 45 months) for sMDS and 55 months (32 to 125 months) for acute leukemia.

Renal Toxicity

In ERASMUS, 8 patients (<1%) developed renal failure 3 to 36 months following lutetium Lu 177 dotatate injection. Two of these patients had underlying renal impairment or risk factors for renal failure (eg, diabetes or hypertension) and required dialysis. Administer the recommended amino acid solution before, during, and after BRAVNETSA to decrease the reabsorption of lutetium Lu 177 dotatate through the proximal tubules and decrease the radiation dose to the kidneys. Advise patients to hydrate and to urinate frequently before, on the day of, and the day after administration of BRAVNETSA. Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue BRAVNETSA based on the severity of renal toxicity. Patients with baseline renal impairment may be at increased risk of toxicity due to increased radiation exposure.

Hepatotoxicity

In ERASMUS, 2 patients (<1%) were reported to have hepatic tumor hemorrhage, edema, or necrosis, with 1 patient experiencing intrahepatic congestion and cholestasis. Patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure. Monitor transaminases, bilirubin, serum albumin, and the international normalized ratio during treatment. Withhold dose, reduce dose, or permanently discontinue BRAVNETSA based on the severity of hepatotoxicity.

Hypersensitivity Reactions

Hypersensitivity reactions, including angioedema, occurred in patients treated with lutetium Lu 177 dotatate injection. Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis, during and following BRAVNETSA administration for a minimum of 2 hours in a setting where cardiopulmonary resuscitation medication and equipment are available. Discontinue the infusion upon the first observation of any signs or symptoms consistent with a severe hypersensitivity reaction and initiate appropriate therapy. Premedicate patients with a history of Grade 1 or 2 hypersensitivity reactions to BRAVNETSA before subsequent doses. Permanently discontinue BRAVNETSA in patients who experience Grade 3 or 4 hypersensitivity reactions.

Neuroendocrine Hormonal Crisis

Neuroendocrine hormonal crises, manifesting with flushing, diarrhea, bronchospasm, and hypotension, occurred in <1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial lutetium Lu 177 dotatate injection dose. Two patients (<1%) were reported to have hypercalcemia. Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction, or other signs and symptoms of tumor-related hormonal release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated.

Embryo-Fetal Toxicity

BRAVNETSA can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to initiating BRAVNETSA. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 7 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 4 months after the last dose.

Risk of Infertility

BRAVNETSA may cause infertility in males and females. The recommended cumulative dose of 29.6 GBq of BRAVNETSA results in a radiation absorbed dose to the testes and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy.

ADVERSE REACTIONS

The most common Grades 3-4 adverse reactions (≥4% with a higher incidence in the BRAVNETSA arm) are lymphopenia, increased GGT, vomiting, nausea, increased AST, increased ALT, hyperglycemia, and hypokalemia.

DRUG INTERACTIONS

Somatostatin Analogs

Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each BRAVNETSA dose. Administer short-and long-acting octreotide during BRAVNETSA treatment as recommended.

Glucocorticoids

Avoid repeated administration of high doses of glucocorticoids during treatment with BRAVNETSA.

USE IN SPECIFIC POPULATIONS

Advise patients not to breastfeed during BRAVNETSA treatment.

To report SUSPECTED ADVERSE REACTIONS, contact Lantheus at 1-800-362-2668 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for BRAVNETSA.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for more than 70 years. For more information, visit www.lantheus.com.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “expected,” “only,” “positioned,” “look forward,” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) our ability to successfully commercialize BRAVNETSA and achieve market adoption; (ii) the ability of our supply and distribution network to manufacture and deliver BRAVNETSA reliably; (iii) the existence, availability and profile of competing products; (iv) the outcome of pending or future litigation; and (v) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q).

References:

¹Neuroendocrine Tumors. Cleveland Clinic. Published June 26, 2024. Accessed May 22, 2025. https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

²Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID: 28448665; PMCID: PMC5824320.

³Kolarova T, et.al. P-136 Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability. Annals of Oncology, Volume 31, S134.

⁴Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017 Mar 13;189(10):E398-E404. doi: 10.1503/cmaj.160771. PMID: 28385820; PMCID: PMC5359105.

LUTATHERA^® is a registered trademark of Novartis AG and/or its affiliates.

Contacts:

Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com

SHENZHEN, CHINA, Sept. 22, 2026 (GLOBE NEWSWIRE) — Lianhe Sowell International Group Ltd (Nasdaq: LHSW) (the “Company”), a provider of industrial machine vision products and solutions in China, today announced that it has entered into a strategic cooperation agreement (the “Agreement”) with Kumquat Technology Co., Ltd. (“Kumquat Technology”), a subsidiary of Chery Group and the operating entity for its nationwide network of 1,000 4S stores, to promote intelligent equipment solutions across China’s automotive aftermarket.

Under the Agreement, the two companies will collaborate on intelligent equipment solutions covering 24 automotive aftermarket processes. Lianhe Sowell will provide complete sets of intelligent operating equipment, while Kumquat Technology will provide supporting automotive parts. The parties will also leverage their respective resources and capabilities to promote the solutions in the domestic market.

Kumquat Technology serves as the operating entity for Chery Group’s nationwide network of 1,000 4S stores, providing automotive aftermarket products and services through its extensive distribution and service network. Under the Agreement, Kumquat Technology will leverage this network to promote Lianhe Sowell’s intelligent equipment products to partner stores and downstream customers.

As part of the cooperation, demonstration sites for Lianhe Sowell’s intelligent equipment will be established at selected locations provided by Kumquat Technology, offering Kumquat Technology’s partner customers opportunities to experience the equipment and supporting product promotion.

Beyond the domestic market, the parties intend to explore overseas opportunities, with Kumquat Technology leading market development and operations and Lianhe Sowell providing products and technical support. The cooperation will also include cross-channel promotion of Kumquat Technology’s automotive aftermarket parts to Lianhe Sowell’s industry customers.

“We are pleased to establish this strategic cooperation with Kumquat Technology and expand the application of our intelligent equipment solutions across the automotive aftermarket,” said Mr. Yue Zhu, Chief Executive Officer and Director of the Company. “By combining Kumquat Technology’s automotive industry resources, channel network and aftermarket capabilities with our capabilities in intelligent equipment and industrial automation, we believe this cooperation can support the adoption of intelligent solutions across automotive aftermarket operations. We look forward to working together to develop a scalable model for intelligent upgrades in China and explore additional opportunities in international markets.”

About Lianhe Sowell International Group Ltd

Lianhe Sowell International Group Ltd (Nasdaq: LHSW) provides industrial vision and industrial robotics solutions. With expertise in the field of machine vision and intelligent equipment, the Company specializes in smart transportation, industrial automation, artificial intelligence, and machine vision. Committed to offering comprehensive intelligent solutions to customers worldwide, the Company continuously advances the intelligent transformation of various industries through technological innovation. For more information, please visit: https://sowellai.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “plan” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risk factors discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Lianhe Sowell International Group Ltd
Email: ir@cnsoftweIl.com
WFS Investor Relations Inc.
Email: services@wfsir.com 
Phone: +1 628 283 9214

DOE-funded study findings could help Nuclear Lifecycle Innovation Campuses evaluate integrated recycling and disposition strategies

BERKELEY, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced results from a three-year U.S. Department of Energy-funded project showing that deep borehole disposal could provide a safe and cost-effective pathway for permanent disposal of waste generated by recycling used nuclear fuel.

Deep Isolation’s analysis performed as part of the project found that all disposal scenarios studied were projected to cost less than the program’s target of 0.1 cent per kilowatt-hour of electricity generated. Long-term safety analyses also found that all scenarios under expected conditions met the study’s safety performance criteria, with projected public radiation doses in most scenarios analyzed orders of magnitude below the 10 millirem-per-year regulatory benchmark used in the analysis. The results of the study could help address an important challenge facing the nuclear industry: how to safely and economically manage waste from future nuclear fuel recycling.

The research was conducted as part of the Department of Energy’s ARPA-E CURIE program in collaboration with Argonne National Laboratory, Oklo Inc. (NYSE: OKLO) and Case Western Reserve University. Deep Isolation developed the waste disposal component of the project, evaluating how waste from recycled nuclear fuel could be packaged and permanently isolated in deep boreholes.

“This project shows the value of designing recycling and disposal systems together rather than treating waste management as a downstream consideration,” said Jesse Sloane, Executive Vice President of Engineering at Deep Isolation. “Working alongside Argonne National Lab and Oklo, we developed a technically grounded disposal pathway that could support the economics of future fuel recycling while safely isolating the resulting waste. These findings give us another important building block toward an integrated and sustainable nuclear fuel cycle.”

Deep Isolation’s work focused on the full disposal pathway for waste produced through fuel recycling, from understanding the waste and how it would be packaged to designing a repository and evaluating its long-term safety and economics. The analysis considered Deep Isolation’s Universal Canister System (UCS) in both horizontal and vertical deep borehole configurations.

Oklo is developing an integrated fuel strategy for used fuel recycling, fuel fabrication, and power generation. It plans to recover usable fuel materials through pyroprocessing, fabricate that material into fuel, and use that fuel in its advanced fast reactors.

“Closing the fuel cycle is about unlocking the full value of used nuclear fuel — recovering its energy potential and extracting isotopes, while safely and permanently managing what remains,” said Ed Petit de Mange, Vice President of Fuel Recycling at Oklo. “This three-year study shows what’s possible when we design recycling and disposal together: an integrated approach that can meet rigorous safety standards while keeping disposal costs low. That’s the model we should work toward as we build the infrastructure for a more complete nuclear fuel cycle.”

Hosts of Nuclear Lifecycle Innovation Campuses, a new Department of Energy effort to strengthen and modernize the nation’s full nuclear fuel cycle, are exploring fuel recycling as a previously untapped energy resource. Within each Innovation Campus, permanent disposal will remain an essential part of managing the resulting waste. The CURIE findings could help Deep Isolation, fuel-cycle companies and advanced reactor developers plan recycling and disposal together from the outset to meet a campus’ needs, supporting a more integrated approach to the future nuclear fuel cycle. 

“CURIE was structured to address several of the technical and economic challenges that need to be considered together as fuel recycling technologies advance,” said Krista Hawthorne, Section Manager, Pyroprocess Engineering, at Argonne National Laboratory. “By bringing together expertise in oxide reduction, process monitoring, fuel-cycle planning and waste disposal, this team has developed a more integrated understanding of how these systems could work together. Deep Isolation’s disposal work provides an important component of that broader fuel-cycle strategy.”

The CURIE project builds on Deep Isolation’s broader ARPA-E-funded work advancing integrated nuclear waste solutions, including the development of the UCS through Project UPWARDS under ARPA-E’s ONWARDS program. The triple-purpose UCS is designed to support storage, transportation and disposal of a range of advanced reactor and fuel-cycle waste streams.

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. When commercialized, Deep Isolation’s solution will offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is being designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System was developed through a three-year project funded by the U.S. Department of Energy’s Advanced Research Projects Agency–Energy and is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact
Sophie McCallum
media@deepisolation.com

Investor Contact
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards and our ability to finalize negotiations on same; our failure to manage our growth effectively or to execute our business plan; our failure to sustain and expand relationships with governmental entities and strategic partners; a failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law.

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Reports on Form 10-K and 10-Q for the fiscal year ended December 31, 2025 and the quarter ending March 31, 2026, respectively, as filed with the SEC on March 30, 2026, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation at InvestorRelations@deepisolation.com or CorpSec@deepisolation.com.

Naples, Italy and Hamilton, Bermuda, Sept. 22, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games as well as ownership and growth of its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced Savoia’s plans to secure an operating concession for Stadio Alfredo Giraud (“Stadio Giraud”), the home ground of the Club, and develop it into a strategic asset for long-term growth.

A Three-Phase Process

The Municipality of Torre Annunziata has structured the path to the Stadio Giraud concession in three phases. The first was an expression of interest, in which participants were asked to submit a detailed program for the stadium’s use and development. Two parties took part, and Savoia’s proposal was judged the most responsive to the municipality’s requirements and objectives.

The second phase concerned the assignment of the stadium’s use, either temporary or continuous. Savoia applied for continuous use and has already been notified of a positive outcome. In the coming days, the Club expects to sign a formal agreement with the municipality granting exclusive use of Stadio Giraud, from 8:00 a.m. to 10:00 p.m., for its teams’ activities. This agreement is independent of the outcome of the concession tender and will cover the entire 2026/2027 football season, expiring on June 30, 2027.

The Path Ahead: The Concession Tender

The next step will be the tender for the stadium’s concession itself, expected to be published by the end of October, initially for a five-year term. Based on that timeline, Savoia anticipates roughly one month for the publication period and a further month for the submission of documentation and offers, with the award expected in January 2027. Savoia considers its position solid: under the municipality’s rules, the tender awards points based on specific criteria, and two of them favor Savoia directly: being the highest-ranked football club based in the city and having the deepest historical ties to local football. Savoia currently competes in Serie C and has long been the city’s leading team, meeting both criteria. The Club expects this to translate into a high score and limited competition from other bidders. Even so, the final terms, including the required investment, obligations and overall economic conditions of the concession, will only be known once the tender is officially published, and the Club will evaluate them carefully before proceeding. The final assignment, in any case, remains subject to the outcome of the public tender process.

Beyond a Matchday Venue: A Strategic Asset

In the Club’s vision, Stadio Giraud is not simply the ground on which the first team plays its matches. Direct management of the stadium would allow Savoia progressively to transform it into a genuine strategic asset capable of generating revenue, strengthening the Club’s relationship with the local community, and contributing to the growth of the Club’s overall value.

A Strategic Location

Stadio Giraud benefits from a particularly favorable location, being close to the Torre Annunziata motorway exit and along the Naples–Salerno corridor which is one of the principal transportation routes in Campania, Pompei, the Amalfi Coast, and Southern Italy. That location, combined with the potential of the surrounding area, underpins much of the Club’s interest in the concession.

New Commercial, Sponsorship and Hospitality Opportunities

The stadium’s location and the possibility of direct management could, over time, enable Savoia to develop activities that extend beyond the purely sporting use of the venue, creating new commercial, sponsorship, hospitality, events and service opportunities. As part of the Club’s broader sustainability model, Stadio Giraud could become not merely a sporting facility, but an asset that strengthens the Club’s finances over time and deepens its ties to the local community.

Stadio Alfredo Giraud in Torre Annunziata

A Long-Term View

“Stadio Giraud is a strategic asset in Savoia Calcio’s long-term growth plan. Our ambition is to progressively transform it into a modern, sustainable venue that is active throughout the week and can become a benchmark for sports infrastructure in Southern Italy. Its strategic location, in the heart of the Vesuvian area and along the Naples–Salerno corridor, combined with the space available within the stadium complex, provides significant potential to develop hospitality, food and beverage, commercial activities and additional services, subject to the terms of the future concession and the relevant approvals. We want Stadio Giraud to be more than just the home of Savoia. Our goal is to create an infrastructure capable of generating long-term sporting, social and economic value for the Club, for Torre Annunziata and for the wider region.”

–  General Manager and Chief Operating Officer of Savoia, Nazario Matachione.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company is actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

• Stadio Alfredo Giraud in Torre Annunziata